These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 3562851)

  • 21. Comparison of central effects of noradrenaline and dopamine injected into the lateral brain ventricle in rats.
    Zebrowska-Lupina I; Malec D; Kleinrok Z
    Acta Physiol Pol; 1975; 26(3):261-74. PubMed ID: 1242288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of passive avoidance behaviour of rats by intracerebroventricular administration of cholecystokinin octapeptide sulfate ester and nonsulfated cholecystokinin octapeptide.
    Kádár T; Fekete M; Telegdy G
    Acta Physiol Acad Sci Hung; 1981; 58(4):269-74. PubMed ID: 6291322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipodal central effects of dopamine and apomorphine [proceedings].
    Koc BA; Marley E
    Br J Pharmacol; 1977 Jun; 60(2):269P-270P. PubMed ID: 880438
    [No Abstract]   [Full Text] [Related]  

  • 24. Noradrenergic influences on dopamine-dependent behaviour in rats [proceedings].
    Pycock C
    Br J Pharmacol; 1976 Jul; 57(3):424P. PubMed ID: 974325
    [No Abstract]   [Full Text] [Related]  

  • 25. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN; Thakar JH; Grimes JD
    Adv Neurol; 1990; 53():219-23. PubMed ID: 2239461
    [No Abstract]   [Full Text] [Related]  

  • 26. Electrophysiological effects of cholecystokinin: central dopaminergic systems.
    Wang RY; White FJ
    Prog Clin Biol Res; 1985; 192():95-103. PubMed ID: 4080721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral evidence for cholecystokinin-opiate interactions in neonatal rats.
    Weller A; Blass EM
    Am J Physiol; 1988 Dec; 255(6 Pt 2):R901-7. PubMed ID: 3202224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine receptor mechanisms: behavioral and electrophysiological studies.
    Ungerstedt U; Ljungberg T; Schultz W
    Adv Biochem Psychopharmacol; 1978; 19():311-21. PubMed ID: 29451
    [No Abstract]   [Full Text] [Related]  

  • 29. Differences in behavioural effects of amphetamine and dopamine-related gene expression in wild-type and homozygous CCK2 receptor deficient mice.
    Rünkorg K; Värv S; Matsui T; Kõks S; Vasar E
    Neurosci Lett; 2006 Oct; 406(1-2):17-22. PubMed ID: 16916582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods for assessing the adverse effects of foods and other chemicals on animal behavior.
    Vorhees CV
    Nutr Rev; 1986 May; 44 Suppl():185-93. PubMed ID: 2980850
    [No Abstract]   [Full Text] [Related]  

  • 31. Functional studies of cholecystokinin-dopamine co-existence: electrophysiology and behavior.
    Skirboll LR; Crawley JN; Hommer DW
    Prog Brain Res; 1986; 68():357-70. PubMed ID: 3562851
    [No Abstract]   [Full Text] [Related]  

  • 32. Cholecystokinin (CCK): ascension from gut to brain.
    Psychopharmacol Bull; 1983; 19(3):347-63. PubMed ID: 6314422
    [No Abstract]   [Full Text] [Related]  

  • 33. Intracerebroventricular administration of cholecystokinin inhibits the activity of the dopaminergic and serotoninergic systems of the brain.
    Vasar EE; Otter MYa ; Ryago LK
    Neurosci Behav Physiol; 1985; 15(3):232-6. PubMed ID: 2993947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of cholecystokinin on dopamine metabolism in the rat brain].
    Kogan BM; Khristoliubova NA; Anokhin KV
    Biull Eksp Biol Med; 1982 Aug; 94(8):42-3. PubMed ID: 7126854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intracerebroventricular administration of cholecystokinin inhibits the dopamine- and serotoninergic systems of the brain].
    Vasar EE; Otter MIa; Riago LK
    Fiziol Zh SSSR Im I M Sechenova; 1982 Sep; 68(9):1218-22. PubMed ID: 7173435
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.